ImmunoPrecise, Twist collaborate on novel therapeutics

By The Science Advisory Board staff writers

October 27, 2020 -- ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.

The early discovery collaboration will expand on Talem's diverse antibody pipeline by exploring ImmunoPrecise's technology in a wide range of oncology targets. ImmunoPrecise will contribute targets and the genetic sequences for lead antibodies against the selected targets. Twist Biopharma, a division of Twist Bioscience, will design synthetic antibody libraries based on the provided antibody repertoire sequences from immunized animals to discover optimized, humanized lead antibody candidates.

The companies aim to jointly advance the programs through proof-of-concept and preclinical development and will collaborate on any commercial opportunities generated by the efforts that may result in milestones or key preclinical, clinical, and commercial milestones as well as royalties for any antibodies resulting from the collaboration.

ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine
ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.
ImmunoPrecise subsidiary expands B cell Select platform
IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's...
ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2.
Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter